Sign In
2 Dec 2019 07:00
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Nigerian order for VISITECT® CD4
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Company has received a second conditional purchase order for its VISITECT® CD4 350 test.
The order is for 200,000 tests, currently scheduled for delivery as follows, subject to the approval noted below:
·; 50,000 tests in January 2020
·; 50,000 tests in February 2020
·; 100,000 tests in March 2020
This order is in addition to the first purchase order for 50,000 tests announced on 16 August 2019. The combined order total for 250,000 tests remains conditional upon the Nigerian Ministry of Health ("MOH") approving the Company's VISITECT® CD4 350 test into its national HIV policy, a process which is still ongoing at present. A final delivery schedule will be confirmed once the MOH outcome is known with certainty.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Hannah Boros (Corporate Finance) | |
Camille Gochez (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Follow the stocks
